Resveratrol

Resveratrol is the compound that turned the aging field into a consumer market. In 2003, David Sinclair's lab reported that resveratrol activated SIRT1 in yeast and extended lifespan, and reproduced parts of the effect in mice. That paper triggered GlaxoSmithKline's $720 million acquisition of Sirtris in 2008. It is also the reason resveratrol became the default "longevity molecule" on supplement labels for two decades.

Since then, resveratrol has been tested in more randomised controlled trials than any other longevity molecule in our database. A 2024 systematic review identified 137 published RCTs on pure resveratrol, covering 104 unique trials and more than 4,800 subjects. 92 studies (67 percent) reported a positive effect on their primary endpoint. 42 studies (31 percent) reported no effect. That is a lot of human data. It is not a lot of consensus.

The single most important 2025 paper is a GRADE-assessed systematic review and dose-response meta-analysis of 11 RCTs measuring resveratrol's effect on SIRT1 itself, the sirtuin the commercial narrative is built on. The pooled result: no significant effect on SIRT1 gene expression, no significant effect on protein expression, no significant effect on serum SIRT1 levels. The mechanism marketed as the longevity effect is not confirmed at the doses and durations most trials use. This is our central nuance for the sirtuin story: resveratrol has plenty of human data on metabolic and cardiovascular markers, but the specific SIRT1 activation sold on labels does not hold up in pooled human data.

The heterogeneity across trials tracks dose and population, not just resveratrol vs placebo. A 52-week phase II trial in mild-to-moderate Alzheimer's (n=119) escalating from 500 mg per day to 1,000 mg twice per day was safe, reduced Aβ40 and MMP9 in cerebrospinal fluid, and shifted neuroinflammation markers. A PREDIMED substudy (n=1,000) linked higher urinary resveratrol metabolites to lower fasting glucose and triglycerides in a high-cardiovascular-risk cohort. A crossover trial of 45 overweight adults on 150 mg per day for four weeks found no effect on cardiovascular markers, endothelial function, or inflammation. Same molecule, three very different signals, depending on dose and who is being dosed.

Bioavailability is the practical constant. Oral resveratrol is conjugated by phase-II liver enzymes and excreted so fast that plasma levels rarely reach the concentrations that drove the mouse and yeast work. This is why some formulations pair resveratrol with piperine to slow metabolism, or use liposomal, micronised, or trans-resveratrol crystalline forms to raise blood levels. Higher plasma exposure does not automatically translate to better clinical endpoints in people, but every discussion of "does resveratrol work" that ignores bioavailability is talking about the wrong molecule.

Preclinical work still supports plausible mechanisms: direct antioxidant activity, indirect AMPK activation, anti-inflammatory effects, mild vasodilation. It is safe at typical doses of 150-500 mg per day. But the NIH Interventions Testing Program, which tests candidate longevity molecules for lifespan effects in genetically heterogeneous mice, reported no lifespan extension for resveratrol on standard diet.

Where the human evidence is strongest is in metabolic subgroups: type-2 diabetes glucose control, flow-mediated dilation in older adults, some CRP and TNF-alpha reductions in inflammatory populations. That is different from an anti-aging claim. It is also different from what the label on most resveratrol bottles implies.

The RIPE study at the University of Florida is worth flagging for anyone actually deciding whether to take resveratrol long-term. It is a two-year randomised trial comparing 300 mg per day and 1,000 mg per day against placebo, with cognitive and physical performance as primary endpoints in older adults. Full outcome data has been slow to publish. When it does, it will be one of the few pieces of evidence that can actually answer the "does it do anything meaningful over years" question that supplement buyers are implicitly asking.

Our plain take: resveratrol has real, dose-dependent effects on some cardiovascular and metabolic endpoints in specific populations, no confirmed effect on the SIRT1 mechanism most brands market it for, and no clear anti-aging signal in healthy adults. If you're taking it for metabolic-syndrome-adjacent reasons, the case is defensible. If you're taking it because it "activates sirtuins for longevity," the 2025 GRADE meta-analysis says that specific claim doesn't survive pooling.

Resveratrol and periodontitis (2025 trial)

One randomized trial tested 500 mg/day for 180 days as an adjunct to full-mouth ultrasonic debridement in 38 smokers with Stage III/IV Grade C periodontitis. At 12 months, probing depth was 2.80 mm with resveratrol vs 3.02 mm with placebo (p<0.05), clinical attachment level 3.87 vs 4.39 mm 1. A commentary flagged the small single-center all-smoker sample 2. This is a gum-healing adjunct result in smokers. It is not evidence for resveratrol as a longevity supplement, and the trial did not measure epigenetic age. A cross-sectional NHANES analysis linking severe periodontitis to 1.35 to 2.12 extra epigenetic clock years is association only, not cause 3.

Products with this: Resveratrol